MERRIMACK PHARMACEUTICALS INC MACK Income Statement

Merrimack pharmaceuticals inc (MACK)

Income statement / Quarterly

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11
Operating expenses:
License and collaboration revenues
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	16,440	36,558	14,842	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Collaboration revenues
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	16,440	36,558	14,842	23,445	28,002	27,815	13,034	7,823	6,856	18,452	14,655	14,191	11,323	12,063	11,344	12,577	8,582	6,595	6,461
Research and development expenses
-	0	0	4,739	6,361	10,231	12,959	13,678	13,106	12,360	13,598	19,751	21,605	25,621	28,247	27,695	28,002	4,785	37,763	42,806	35,679	-4,441	43,632	33,795	30,324	30,055	37,630	42,465	36,989	34,564	30,885	28,758	31,651	27,529	23,913	31,187	18,001
General and administrative expenses
1,935	2,211	4,346	5,929	3,683	4,041	3,777	3,513	4,270	4,654	3,366	14,798	5,634	-	6,448	8,138	-	-	-	-	-	-3,474	8,095	7,921	6,224	-	5,150	5,095	4,932	4,155	4,312	3,610	3,728	3,215	3,306	4,832	3,101
Gain on sale of assets
2,139	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gain on deconsolidation of Silver Creek Pharmaceuticals, Inc.
-	-	-	-	-	-	-	-	-	-	10,848	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gain on sale of assets
-	-	-	1,410	-	-	-	-	-	-	-	1,703	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total operating (income) expenses
-204	2,211	846	9,258	10,044	14,272	16,736	17,191	17,376	17,014	16,964	34,549	27,239	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
General and administrative expenses
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	6,452	-	16,956	12,315	9,189	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Restructuring expenses
-	-	-	-	-	-	-	-	-	-	-	-	-	-	809	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total costs and expenses
-	-	-	-	-	-	-	-	-	-	-	-	-	41,536	35,504	35,833	34,454	-9,627	54,719	55,121	44,868	-7,915	51,727	41,716	36,548	36,065	42,780	47,560	41,921	38,719	35,197	32,368	35,379	30,744	27,219	36,019	21,102
Income (loss) from operations
204	-2,211	-846	-9,258	-10,044	-14,272	-16,736	-17,191	-17,376	-17,014	-16,964	-34,549	-27,239	-41,536	-35,504	-35,833	-34,454	-58,213	-38,279	-18,563	-30,026	31,360	-23,725	-13,901	-23,514	-28,242	-35,924	-29,108	-27,266	-24,528	-23,874	-20,305	-24,035	-18,167	-18,637	-29,424	-14,641
Other income and expenses:
Interest income
45	65	140	207	365	436	306	282	275	249	250	382	14	18	64	122	72	5	13	34	47	52	7	20	35	43	36	35	52	57	64	54	9	5	8	29	14
Interest expense
-	1	0	1,049	478	-	472	-	-	4,250	1,659	26,762	1,979	1,741	1,560	15,858	3,290	5,245	4,476	4,482	4,566	4,564	4,585	4,570	4,511	4,479	3,946	1,293	1,220	-	-	-	1	1	2	4	6
Other expense, net
-	0	1	670	-301	-1,452	-237	-860	-681	-841	69	-659	-2	-286	385	-64	-43	338	356	110	113	151	265	161	236	330	71	115	111	130	490	112	625	-58	-93	203	1,098
Total other income and expenses
45	64	141	-172	-414	-1,500	-403	-578	-406	-4,842	9,508	-25,336	-1,967	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net loss from continuing operations before income tax benefit
-	-	-	-	-	-	-17,139	-	-	-	-7,456	-59,885	-	-	-36,615	-51,633	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Income tax benefit
-	-	-	-	-	-	-4,798	-	-	-	-2,133	-30,239	-	-	-9,770	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net loss from continuing operations
-	-	-	-	-	-	-12,341	-	-	-11,829	-5,323	-29,646	-29,206	-40,091	-26,845	-51,633	-37,715	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Discontinued operations:
Income from discontinued operations, net of tax
-	-	-	-	-	-	16,330	-	-	-1,122	8,456	540,485	-947	6,464	-3,430	675	-943	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net (loss) income
-	-	-	-	-	-	-	-	-	-12,951	3,133	510,839	-30,153	-33,627	-30,275	-50,958	-38,658	-48,068	-42,386	-22,901	-34,432	-9,477	-28,038	-18,290	-27,754	-32,348	-39,763	-30,251	-28,323	-24,893	-23,320	-20,139	-23,402	-18,221	-18,724	-29,196	-13,535
Net loss attributable to non-controlling interest
-	-	-	-	-	-	-	-	-	0	31	-724	-467	-1,178	-207	-208	-185	-242	208	-123	327	219	-137	-181	-169	711	-132	-169	-170	-125	-121	-113	-118	-105	-125	-145	-78
Net income (loss)
249	3,261	-705	-9,430	-10,458	-8,944	3,989	-17,769	-17,782	-12,951	3,102	511,563	-29,686	-32,449	-30,068	-50,750	-38,473	-47,826	-42,594	-22,778	-34,759	-9,696	-27,901	-18,109	-27,585	-33,059	-39,631	-30,082	-28,153	-24,768	-23,199	-20,026	-23,284	-18,116	-18,599	-29,051	-13,457
Net loss from continuing operations
-	-	-	-	-	-	-	-	-	-11,829	-5,354	-28,922	-28,739	-38,913	-26,638	-51,425	-37,530	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Income from discontinued operations, net of tax
-	-	-	-	-	-	-	-	-	-1,122	8,456	540,485	-947	6,464	-3,430	675	-943	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net loss
249	3,261	-705	-9,430	-10,458	-8,944	3,989	-17,769	-17,782	-12,951	3,102	511,563	-29,686	-32,449	-30,068	-50,750	-38,473	-47,825	-42,594	-22,779	-34,759	-9,696	-27,901	-18,109	-27,585	-33,059	-39,631	-30,082	-28,153	-24,768	-23,199	-20,026	-23,284	-18,116	-18,599	-29,051	-13,457
Other comprehensive income:
Unrealized gain on marketable securities
-	0	0	0	9	-4	-4	11	-12	-	-	-	-	-	-3	15	-14	0	6	21	47	-31	-40	5	16	-8	-11	15	18	-	59	-49	-	-	-	-	-
Other comprehensive income
-	-	-	-	9	-	-4	-	-	-	-	-	-	-	-3	15	-14	0	6	21	47	-31	-40	5	16	-8	-11	15	18	-	59	-49	-	-	-	-	-
Comprehensive income (loss)
249	3,261	-705	-9,430	-10,449	-8,948	3,985	-17,758	-17,794	-12,951	3,102	511,563	-29,686	-32,447	-30,071	-50,735	-38,487	-47,826	-42,588	-22,757	-34,712	-9,727	-27,941	-18,104	-27,569	-33,067	-39,642	-30,067	-28,135	-24,816	-23,140	-20,075	-23,284	-	-18,599	-29,051	-
Basic and dilutive net loss per common share
Net loss from continuing operations
-	-	-	-	-	-	-0.92	-	-	-0.88	-0.40	-2.18	-2.20	-9.54	-2.06	-0.41	-0.32	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net income from discontinued operations, net of tax
-	-	-	-	-	-	1.22	-	-	-0.04	0.64	40.80	-0.07	0.49	-0.27	0.01	-0.01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net income (loss) per common share - basic and diluted
0.02	0.24	-0.05	-0.71	-0.78	-0.67	0.30	-1.33	-1.33	-0.92	0.24	38.62	-2.27	-9.05	-2.33	-0.40	-0.33	-12.38	-0.38	-0.21	-0.32	-7.27	-0.27	-0.17	-0.27	-0.33	-0.39	-0.31	-0.29	1.33	-0.25	-0.22	-2.14	-	-1.81	-2.76	-
Weighted-average common shares used to compute basic and diluted net loss per common share
13,380	13,368	13,357	13,344	13,343	13,343	13,343	13,343	13,343	13,341	13,282	13,246	13,059	-205,014	12,921	126,161	116,064	-284,996	112,417	109,975	107,148	-269,804	104,871	103,809	102,888	102,472	101,155	96,170	95,879	95,173	93,724	90,581	11,846	-	11,389	11,282	-
Cash dividends paid per common share
-	-	-	-	-	-	-	-	-	-	-	10.55	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net loss per share available to common stockholders-basic (in dollars per share)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1.35
Net loss per share available to common stockholders-diluted (in dollars per share)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1.35
Weighted-average common shares used in computing net loss per share available to common stockholders-basic (in shares)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	11,106
Weighted-average common shares used in computing net loss per share available to common stockholders-diluted (in shares)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	11,106